Amedeo Smart

Free Medical Literature Service



Ovarian Neoplasms

  Free Subscription

Articles published in
Oncol Rep
    November 2022
  1. WANG T, Liu J, Huang X, Zhang C, et al
    Gomisin A enhances the antitumor effect of paclitaxel by suppressing oxidative stress in ovarian cancer.
    Oncol Rep. 2022;48.
    >> Share

  2. LI J, Li D, Zhang W
    [Retracted] Tumor suppressor role of miR-217 in human epithelial ovarian cancer by targeting IGF1R.
    Oncol Rep. 2022;48.
    >> Share

    June 2022
  3. HE M, Sun HG, Hao JY, Li YL, et al
    [Corrigendum) RNA interferencemediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycininduced apoptosis dependent on JNK activation.
    Oncol Rep. 2022;47.
    >> Share

    May 2022
  4. ZHANG Q, Ding J, Wang Y, He L, et al
    Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review).
    Oncol Rep. 2022;47.
    >> Share

    April 2022
  5. ZHOU X, Zhao F, Wang ZN, Song YX, et al
    [Corrigendum] Altered expression of miR152 and miR148a in ovarian cancer is related to cell proliferation.
    Oncol Rep. 2022;47.
    >> Share

  6. YANG L, Xie HJ, Li YY, Wang X, et al
    Molecular mechanisms of platinumbased chemotherapy resistance in ovarian cancer (Review).
    Oncol Rep. 2022;47.
    >> Share

    March 2022
  7. PARK SA, Kim LK, Park HM, Kim HJ, et al
    Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
    Oncol Rep. 2022;47.
    >> Share

    October 2021
  8. CHENG L, Zhang D, Yan W
    Ultrasoundtargeted microbubble destructionmediated overexpression of Sirtuin 3 inhibits the progression of ovarian cancer.
    Oncol Rep. 2021;46.
    >> Share

  9. LI H, Liu Y, Wang Y, Zhao X, et al
    Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).
    Oncol Rep. 2021;46.
    >> Share

  10. CUI S, Li F
    RHPN1AS1 promotes ovarian carcinogenesis by sponging miR68845p thus releasing TOP2A mRNA.
    Oncol Rep. 2021;46.
    >> Share

    September 2021
  11. PAN Y, Zhang L, Zhang X, Liu R, et al
    [Retracted] Synergistic effects of eukaryotic coexpression plasmidbased STAT3specific siRNA and LKB1 on ovarian cancer in vitro and in vivo.
    Oncol Rep. 2021;46.
    >> Share

    August 2021
  12. WEN J, Han S, Cui M, Wang Y, et al
    [Retracted] Long noncoding RNA MCM3APAS1 drives ovarian cancer progression via the microRNA1433p/TAK1 axis.
    Oncol Rep. 2021;46.
    >> Share

    June 2021
  13. CUI S, Li C
    RHPN1AS1 promotes ovarian carcinogenesis by sponging miR4855p and releasing TPX2 mRNA.
    Oncol Rep. 2021;45.
    >> Share

    May 2021
  14. ZHONG Y, Le F, Cheng J, Luo C, et al
    Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatinresistant SKOV3/DDP ovarian cancer cells.
    Oncol Rep. 2021;45.
    >> Share

  15. LIANG X, Ju J
    Matrine inhibits ovarian cancer cell viability and promotes apoptosis by regulating the ERK/JNK signaling pathway via p38MAPK.
    Oncol Rep. 2021;45.
    >> Share

  16. LI M, Zhang S, Ma Y, Yang Y, et al
    Role of hsamiR105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
    Oncol Rep. 2021;45.
    >> Share

  17. FREUND E, Miebach L, Stope MB, Bekeschus S, et al
    Hypochlorous acid selectively promotes toxicity and the expression of danger signals in human abdominal cancer cells.
    Oncol Rep. 2021;45.
    >> Share

    April 2021
  18. CAO S, Chen C, Xue J, Huang Y, et al
    [Corrigendum] Silencing of type Igamma phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion.
    Oncol Rep. 2021;45:1.
    >> Share

  19. LEE SY, Kwon J, Lee KA
    Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1.
    Oncol Rep. 2021;45.
    >> Share

  20. CHEN J, Chen H, Pan L
    SIRT1 and gynecological malignancies (Review).
    Oncol Rep. 2021;45.
    >> Share

    December 2020
  21. WEI L, He Y, Bi S, Li X, et al
    miRNA199b3p suppresses growth and progression of ovarian cancer via the CHK1/Ecadherin/EMT signaling pathway by targeting ZEB1.
    Oncol Rep. 2020 Dec 11. doi: 10.3892/or.2020.7895.
    >> Share

  22. AN Q, Liu T, Wang MY, Yang YJ, et al
    KRT7 promotes epithelialmesenchymal transition in ovarian cancer via the TGFbeta/Smad2/3 signaling pathway.
    Oncol Rep. 2020 Dec 8. doi: 10.3892/or.2020.7886.
    >> Share

  23. ZHAO L, Liu Z, Deng X, Wang J, et al
    Polyphyllin VII induces mitochondrial apoptosis by regulating the PP2A/AKT/DRP1 signaling axis in human ovarian cancer.
    Oncol Rep. 2020 Dec 2. doi: 10.3892/or.2020.7879.
    >> Share

  24. BRUM MCM, Dos Santos Guimaraes I, Ferreira LB, Rangel LBA, et al
    Osteopontinc isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity.
    Oncol Rep. 2020 Dec 1. doi: 10.3892/or.2020.7877.
    >> Share

    November 2020
  25. LEE DW, Lee W, Kwon M, Lee HN, et al
    Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells.
    Oncol Rep. 2020 Nov 11. doi: 10.3892/or.2020.7845.
    >> Share

  26. ZHAO M, Ji H, Fu Q, Cheng Q, et al
    MicroRNA-134-3p inhibits ovarian cancer progression by targeting flap structure-specific endonuclease 1 in vitro.
    Oncol Rep. 2020 Nov 10. doi: 10.3892/or.2020.7844.
    >> Share

    October 2020
  27. ZHANG H, Hu L, Cheng M, Wang Q, et al
    The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
    Oncol Rep. 2020 Oct 9. doi: 10.3892/or.2020.7798.
    >> Share

    September 2020
  28. LIU P, Zhong Y, Cao T, Sheng X, et al
    A frequent somatic mutation in the 3'UTR of GAPDH facilitates the development of ovarian cancer by creating a miR125b binding site.
    Oncol Rep. 2020;44:887-896.
    >> Share

  29. ZHOU S, Wang R, Xiao H
    Adipocytes induce the resistance of ovarian cancer to carboplatin through ANGPTL4.
    Oncol Rep. 2020;44:927-938.
    >> Share

  30. ZHANG R, Chen X, Fu S, Xu L, et al
    A small molecule STAT3 inhibitor, LLL12, enhances cisplatin and paclitaxelmediated inhibition of cell growth and migration in human ovarian cancer cells.
    Oncol Rep. 2020;44:1224-1232.
    >> Share

    July 2020
  31. WEN J, Han S, Cui M, Wang Y, et al
    Long noncoding RNA MCM3APAS1 drives ovarian cancer progression via the microRNA1433p/TAK1 axis.
    Oncol Rep. 2020 Jul 17. doi: 10.3892/or.2020.7694.
    >> Share

    May 2020
  32. PEI Y, Li K, Lou X, Wu Y, et al
    miR1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer.
    Oncol Rep. 2020 May 25. doi: 10.3892/or.2020.7623.
    >> Share

    March 2020
  33. QIN J, Fu M, Wang J, Huang F, et al
    PTEN/AKT/mTOR signaling mediates anticancer effects of epigallocatechin3gallate in ovarian cancer.
    Oncol Rep. 2020 Mar 31. doi: 10.3892/or.2020.7571.
    >> Share

  34. WANG L, Li X
    Identification of an energy metabolismrelated gene signature in ovarian cancer prognosis.
    Oncol Rep. 2020 Mar 17. doi: 10.3892/or.2020.7548.
    >> Share

    February 2020
  35. SHEN JJ, Zhu XF, Xu J, Wang ZF, et al
    Oroxylin A exerts anticancer effects on human ovarian cancer cells via the PPARgammadependent reversal of the progesterone receptor membrane component 1/2 expression profile.
    Oncol Rep. 2020 Feb 21. doi: 10.3892/or.2020.7509.
    >> Share

    December 2019
  36. LIU CL, Pan HW, Torng PL, Fan MH, et al
    SRPX and HMCN1 regulate cancerassociated fibroblasts to promote the invasiveness of ovarian carcinoma.
    Oncol Rep. 2019;42:2706-2715.
    >> Share

    November 2019
  37. GAO S, Bian T, Su M, Liu Y, et al
    miR26a inhibits ovarian cancer cell proliferation, migration and invasion by targeting TCF12.
    Oncol Rep. 2019 Nov 26. doi: 10.3892/or.2019.7417.
    >> Share

    October 2019
  38. DONG J, Xu M
    [Corrigendum] A 19miRNA Support Vector Machine classifier and a 6miRNA risk score system designed for ovarian cancer patients.
    Oncol Rep. 2019 Oct 23. doi: 10.3892/or.2019.7385.
    >> Share

  39. WEI X, Jia Y, Lou H, Ma J, et al
    Targeting YAP suppresses ovarian cancer progression through regulation of the PI3K/Akt/mTOR pathway.
    Oncol Rep. 2019 Oct 14. doi: 10.3892/or.2019.7370.
    >> Share

  40. SUN D, Liu J, Zhou L
    Upregulation of circular RNA circFAM53B predicts adverse prognosis and accelerates the progression of ovarian cancer via the miR646/VAMP2 and miR647/MDM2 signaling pathways.
    Oncol Rep. 2019 Oct 10. doi: 10.3892/or.2019.7366.
    >> Share

    September 2019
  41. ISHIKURA N, Yorozu K, Kurasawa M, Yanagisawa M, et al
    Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
    Oncol Rep. 2019;42:1057-1065.
    >> Share

    August 2019
  42. VACLAVIKOVA R, Klajic J, Brynychova V, Elsnerova K, et al
    Development of highresolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
    Oncol Rep. 2019;42:763-774.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016